3545 results for «218»
3545 results
PCR London Valves 2022 Closing Ceremony
29 Nov 2022 – From PCR London Valves 2022
Bernard Prendergast and the Faculty members celebrate the end of another fantastic edition of PCR London Valves which focused on learning, sharing, training and networking in a friendly environment.
View key facts, figures and great snapshots of what went on during these inspiring 3 days: the best-of #PCRLV...
PCR London Valves 2022 Welcome Ceremony
27 Nov 2022 – From PCR London Valves 2022
Consult this session to watch PCR LV 2022 Welcome Ceremony, and learn more about the track leaders, the programme producers, as well as the latest updates regarding this congress.
A new percutaneous technique for effective vascular access site closure in patients undergoing TAVI and thoraco-abdominal aortic aneurysm repairs
09 Jan 2019
Results of the PASTE study
Authors :
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/whats-new-on-pcronline/2025/esc/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.
Author
